Role of Trimetazidine in Coronary Artery Bypass Graft Surgery - World Journal of Cardiovascular Surgery

WJCS > Vol.7 No.7, July 2017

Role of Trimetazidine in Coronary Artery Bypass Graft Surgery ()

HTML XML

Download as PDF (Size: 740KB) PP. 87-102

DOI: 10.4236/wjcs.2017.77011 1,335 Downloads 3,127 Views Citations

Author(s)

Gerez Fernandes Martins^1*, Gerez Martins²

Affiliation(s)

¹Cardiac Surgery Department, Institute of Cardiology State Aloysio de Castro, Rio de Janeiro, Brazil.
²Cardiology Department, Institute of Cardiology State Aloysio de Castro, Rio de Janeiro, Brazil.

ABSTRACT

Trimetazidine is a drug that has been used to reduce the damage of reperfusion injury, which is a mechanism of oxidative aggression that occurs in coronary syndromes, angioplasty procedures, as well as in cardiovascular surgeries. Seeking to improve myocardial protection during procedures that involve reperfusion, attention was recently turned to research on cytoprotective drugs which act on segments of cellular metabolism, used in isolation or combined to reduce or prevent damage to the cardiac cell. The aim of this review is to objectively evaluate the effects of the drug trimetazidine (TMZ) on ischemia-reperfusion injury in coronary artery bypass graft surgery by reviewing all known studies from recent years.

KEYWORDS

Ischemia-Reperfusion Injury, Oxidative Stress, Inflammation, Trimetazidine, Coronary Artery Bypass Graft

Share and Cite:

Martins, G. and Martins, G. (2017) Role of Trimetazidine in Coronary Artery Bypass Graft Surgery. World Journal of Cardiovascular Surgery, 7, 87-102. doi: 10.4236/wjcs.2017.77011.

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies